|
Match
|
Document |
Document Title |
|
|
US20150273064 |
Pharmaceutical Formulation Containing Gelling Agent
Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically... |
|
|
US20150265605 |
Pharmaceutical Formulation Containing Gelling Agent
Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically... |
|
|
US20090130197 |
EXTENDED RELEASE PELLET FORMULATION CONTAINING PRAMIPEXOLE OR A PHARMACEUTICALLY ACCEPTABLE SALT
An extended release pellet comprising an active ingredient selected from pramipexole and the pharmaceutically acceptable salts thereof, and at least one release-modifying excipient. |
|
|
US20170119664 |
CARBIDOPA/LEVODOPA GASTRORETENTIVE DRUG DELIVERY
A gastroretentive drug formulation for the sustained release of an active agent in the gastrointestinal tract comprises internal layer or compartment comprising an active agent and one or more... |
|
|
US20160120810 |
CRUSH RESISTANT DELAYED-RELEASE DOSAGE FORMS
The invention relates to a dosage form comprising a physiologically effective amount of a physiologically active substance (A), a synthetic, semi-synthetic or natural polymer (C), optionally one... |
|
|
US20160067199 |
NOVEL FORMULATION OF DICLOFENAC
The present invention relates to methods for producing particles of diclofenac using dry milling processes as well as compositions comprising diclofenac, medicaments produced using diclofenac in... |
|
|
US20160058716 |
PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT
Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically... |
|
|
US20160000712 |
Pharmaceutical Formulation Containing Gelling Agent
Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically... |
|
|
US20150359747 |
ABUSE-PROOFED DOSAGE FORM
The invention relates to a dosage form that is thermoshaped without being extruded and that is safeguarded from abuse, comprising at least one synthetic or natural polymer having a breaking... |
|
|
US20150273065 |
Pharmaceutical Formulation Containing Gelling Agent
Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically... |
|
|
US20150238561 |
Compositions of GnRH related compounds and processes of preparation
The present invention provides compositions of GnRH related compounds that are suitable for oral administration, injectable administration and other forms of administration wherein the gelling... |
|
|
US20150216807 |
SOLUBILIZED COQ-10
The present invention is directed to compositions and methods of delivery of CoQ-10 solubilized in monoterpenes. Use of monoterpenes as dissolving agents, greatly effects the ability to... |
|
|
US20150209318 |
PHARMACEUTICAL COMPOSITIONS CONTAINING DIMETHYL FUMARATE
Provided herein are compositions containing compounds, or pharmaceutically acceptable salts, that metabolize to monomethyl fumarate with certain pharmacokinetic parameters and methods for... |
|
|
US20150150978 |
DOSAGE THAT IS SAFEGUARDED FROM ABUSE
The invention relates to a dosage form that is thermoshaped without being extruded and that is safeguarded from abuse, comprising at least one synthetic or natural polymer having a breaking... |
|
|
US20150147391 |
Pharmaceutical Formulation Containing Gelling Agent
Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically... |
|
|
US20150132374 |
FORMULATIONS
A modified release composition comprising cyclosporin A for oral administration. The composition may comprise a core and a modified release coating, wherein the core comprises a hydrogel-forming... |
|
|
US20140370082 |
CYCLOSPORINE ANALOGUE MIXTURES AND THEIR USE AS IMMUNOMODULATING AGENTS
The invention is directed to isomeric mixtures of cyclosporine analogues that are structurally similar to cyclosporine A. The mixtures possess enhanced efficacy and reduced toxicity over the... |
|
|
US20140356294 |
DOSAGE THAT IS SAFEGUARDED FROM ABUSE
The invention relates to a dosage form that is thermoshaped without being extruded and that is safeguarded from abuse, comprising at least one synthetic or natural polymer having a breaking... |
|
|
US20140234410 |
COMBINATION PRODUCTS
A pharmaceutical formulation comprises a plurality of seamless minicapsules having a diameter from 0.5 mm to 5 mm, at least some of the minicapsules containing a methyxanthine as one active... |
|
|
US20140205659 |
CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER
The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of... |
|
|
US20140199388 |
CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER
The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of... |
|
|
US20140199387 |
CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER
The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of... |
|
|
US20140199386 |
CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER
The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of... |
|
|
US20140186437 |
ORAL DOSAGE FORMS WITH THERAPEUTICALLY ACTIVE AGENTS IN CONTROLLED RELEASE CORES AND IMMEDIATE RELEASE GELATIN CAPSULE COATS
The present invention relates to oral dosage form with active agents in controlled release cores and in immediate release gelatin capsule coats. |
|
|
US20140086847 |
DOSAGE FORM THAT IS SAFEGUARDED FROM ABUSE
The invention relates to a dosage form that is thermoshaped without being extruded and that is safeguarded from abuse, comprising at least one synthetic or natural polymer having a breaking... |
|
|
US20120177730 |
Chemosensory Receptor Ligand-Based Therapies
Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a... |
|
|
US20100151013 |
Gastric acid secretion inhibiting composition
An oral pharmaceutical dosage form comprises pharmacologically effective amounts of an acid-susceptible proton pump inhibitor and an H2 receptor antagonist in combination with at least on... |
|
|
US20080311187 |
CRUSH RESISTAN DELAYED-RELEASE DOSAGE FORM
The invention relates to a dosage form comprising a physiologically effective amount of a physiologically active substance (A), a synthetic, semi-synthetic or natural polymer (C), optionally one... |
|
|
US20080152704 |
Dosage Forms of Palonosetron Hydrochloride Having Improved Stability and Bioavailability
Provided are solid oral dosage forms of palonosetron hydrochloride, methods of using the dosage forms to treat emesis, and methods of making the dosage forms. The dosage forms have improved... |
|
|
US20080131501 |
Enhanced immediate release formulations of topiramate
The present invention provides enhanced immediate release formulations of topiramate, in which 80% of the active ingredient is released in the period of time of not more than 30 min. These... |
|
|
US20070202160 |
SOLID-STATE FORM OF CELECOXIB HAVING ENHANCED BIOAVAILABILITY
The selective cyclooxygenase-2 inhibitory drug celecoxib is provided in amorphous form. Also provided is a celecoxib drug substance wherein the celecoxib is present, in at least a detectable... |
|
|
US20170049769 |
Abuse Deterrent Compositions and Methods of Making Same
This invention relates a therapeutic pharmaceutical composition comprising: a mixture including an opioid; polyethylene oxide in an amount of about 3 to about 40 wt % of the composition; a... |
|
|
US20160317456 |
PHARMACEUTICAL COMPOSITIONS
Pharmaceutical compositions containing a therapeutically active agent, a diffusion barrier coating and coating comprising a hydrophobic material. |
|
|
US20160310559 |
Delayed Release Compositions of Linaclotide
The present invention relates to delayed release pharmaceutical compositions comprising linaclotide or pharmaceutically acceptable salts thereof, as well as to various methods and processes for... |
|
|
US20160030289 |
MANUFACTURE OF PEANUT FORMULATIONS FOR ORAL DESENSITIZATION
The present application relates to a method for managing the development and manufacturing process of a therapeutically effective formulation. Peanut proteins are characterized from peanut flour... |
|
|
US20160022588 |
ABUSE-PROOFED ORAL DOSAGE FORM
The present invention relates to an abuse-proofed oral dosage form with controlled release of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol for once daily administration, which... |
|
|
US20150320682 |
NANOPARTICULATE MEGESTROL FORMULATIONS
The present invention is directed to nanoparticulate compositions comprising megestrol. The megestrol particles of the composition have an effective average particle size of less than about 2000 nm. |
|
|
US20150010623 |
CONTROLLED RELEASE PREPARATIONS
Controlled release preparations and soft capsules are provided. Also provided are emulsions and suspensions, including compositions and methods of manufacturing controlled release soft capsules,... |
|
|
US20150004224 |
DPA-ENRICHED COMPOSITIONS OF OMEGA-3 POLYUNSATURATED FATTY ACIDS IN FREE ACID FORM
DPA-enriched pharmaceutical compositions of polyunsaturated fatty acids in free acid form, therapeutic methods for their use, and processes for refining the compositions from fish oil are... |
|
|
US20140248341 |
ALCOHOL RESISTANT ENTERIC PHARMACEUTICAL COMPOSITIONS
Pharmaceutical formulations that resist ethanol-induced dose dumping and methods of use thereof. |
|
|
US20140242159 |
Method for Preparing a Granulate Formulation of Pirfenidone and Pharmaceutically Acceptable Excipients
A capsule formulation of pirfenidone is provided that includes pharmaceutically acceptable excipients. In one embodiment, this capsule formulation is capable of sustaining desirable... |
|
|
US20130337058 |
Micronized Tanaproget and Compositions Containing Same
The present invention provides compositions, desirably pharmaceutical compositions, containing micronized tanaproget. The compositions can also contain microcrystalline cellulose, croscarmellose... |
|
|
US20130052263 |
PHARMACEUTICAL COMPOSITIONS WITH SYNCHRONIZED SOLUBILIZER RELEASE
Pharmaceutical compositions with synchronized solubilizer release as well as various methods associated therewith, are disclosed and described. More specifically, the aqueous solubility of a drug... |
|
|
US20110223244 |
ALCOHOL RESISTANT ENTERIC PHARMACEUTICAL COMPOSITIONS
Pharmaceutical formulations that resist ethanol-induced dose dumping and methods of use thereof. |
|
|
US20110182985 |
Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
The present invention provides pharmaceutical compositions which are effective in providing therapeutically effective blood levels of a therapeutically active ingredient to a subject when... |
|
|
US20050063913 |
Novel metaxalone compositions
The present invention is directed to nanoparticulate compositions comprising metaxalone. The metaxalone particles of the composition have an effective average particle size of less than about 2... |
|
|
US20170000733 |
PHARMACEUTICAL COMPOSITIONS OF AMORPHOUS DISPERSIONS OF DRUGS AND LIPOPHILIC MICROPHASE-FORMING MATERIALS
A pharmaceutical composition comprises a solid amorphous dispersion comprising a low-solubility drug and a concentration-enhancing polymer and a lipophilic microphase-forming material.... |
|
|
US20160361274 |
MODIFIED RELEASE DOSAGE FORMS OF SKELETAL MUSCLE RELAXANTS
A unit dosage form, such as a capsule or the like, for delivering a skeletal muscle relaxant, such as cyclobenzaprine hydrochloride, into the body in an extended or sustained release fashion... |
|
|
US20160346216 |
COMPOSITION AND METHOD FOR AIDING SLEEP
Described is a controlled-release formulation for treating disturbed sleep or insomnia in a subject. The formulation is formulated to release a compound or combination of compounds in sequence at... |
|
|
US20160038411 |
PULSATILE GASTRIC RETENTIVE DOSAGE FORMS
Dosage forms for delayed and pulsed release of therapeutic agents into the stomach are described. The dosage forms are gastric retentive dosage forms that achieve release of the therapeutic agent... |